MARAPHARM VENTURES INC.

Condensed Consolidated Interim Financial Statements () Period Ended (Expressed in Canadian Dollars) Condensed Consolidated Interim Statements of Financial Position Condensed Consolidated Interim Statements of Changes in Shareholders Equity Condensed Consolidated Interim Statements of Comprehensive Loss Condensed Consolidated Interim Statements of Cash Flows Notes to the Condensed Consolidated Interim Financial Statements

Condensed Consolidated Interim Statements of Financial Position As at June 30 March 31 2017 2017 Note $ $ ASSETS () (Audited) CURRENT Cash 2,127,292 4,316,697 Trade and Other Receivables 5 514,276 717,947 Current Portion of Loan Receivable 7 53,110 49,996 Prepaid Expenses and Deposits 6 2,406,584 1,572,972 5,101,262 6,657,612 Loan Receivable 7 240,678 249,231 Due from Related Party 14(a) 306,848 340,507 Property and Equipment 8 4,551,346 2,531,581 Intangible Assets 9 1,830,878 1,618,853 Investment in Associate 12 1,072,566 1,238,132 Total Assets 13,103,578 12,635,916 LIABILITIES CURRENT Trade and Other Payables 10 536,209 656,031 Due to Related Party 14(a) 17,076 25,576 553,285 681,607 Convertible Bonds Payable 11 1,208,857 1,287,676 Total Liabilities 1,762,142 1,969,283 SHAREHOLDERS EQUITY Share Capital 13(b) 29,357,140 26,475,210 Warrant Subscriptions 35,000 - Stock Options Reserve 1,870,301 1,215,195 Share Purchase Warrants Reserve 56,995 91,453 Foreign Currency Translation Reserve (41,912) 124,082 Equity Component of Convertible Bonds 11 213,111 213,111 Deficit (20,149,199) (17,452,418) Total Shareholders Equity 11,341,436 10,666,633 Total Liabilities and Shareholders Equity 13,103,578 12,635,916 Nature of Operations and Ability to Continue as a Going Concern (Note 1) Commitments (Note 15) Segmented Information (Note 16) Subsequent Events (Note 20) The accompanying notes are an integral part of the consolidated financial statements. Approved on behalf of the Board: Linda Sampson Linda Sampson, Director Corey Klassen Corey Klassen, Director 2

Condensed Consolidated Interim Statements of Changes in Shareholders Equity For the Period Ended Note Number of Common Shares Share Purchase Warrants Foreign Currency Translation Equity Component Convertible Share Share Stock Options Total Shareholders Capital Subscriptions Reserve Reserve Reserve Bonds Deficit Equity $ $ $ $ $ $ $ Balance, March 31, 2016 38,032,573 6,674,269 443,000 1,100,628 20,887 17,732 - (7,949,623) 306,893 Shares Issued for Cash 13(b)(i) 5,457,500 1,091,500 (443,000) - - - - - 648,500 Shares Issued for Finders Fees 13(b)(i) 136,500 45,100 - - - - - - 45,100 Shares Issued for Services 13(b)(iii) 320,000 240,000 - - - - - - 240,000 Shares Issued on Exercise of Finders Warrants 13(b)(v) - - - - 23,954 - - - 23,954 Fair Value of Stock Options Cancelled - - - (30,787) - - - 30,787 - Equity Component of Convertible Bonds Issued 12 - - - - - (94,188), (385,692) (479,880) Balance, June 30, 2016 43,946,573 8,050,869-1,069,841 44,841 (76,456), (8,304,528) 784,567 Shares Issued for Cash 13(b)(i) 10,866,250 2,173,250 - - - - - - 2,173,250 Share Issuance Costs (468,581) - - 165,842 - - - (302,739) Shares Issued for Finders Fees 13(b)(i) 352,500 52,700 - - - - - - 52,700 Shares Issued for Intangible Assets 13(b)(ii) 1,172,814 594,855 - - - - - - 594,855 Shares Issued for Services 13(b)(iii) 3,778,547 4,278,478 - - - - - - 4,278,478 Shares Issued for Debt 13(b)(iv) 188,702 137,752 - - - - - - 137,752 Shares Issued on Exercise of Warrants 13(b)(v) 15,712,750 9,823,949 - - (20,887) - - - 9,803,062 Shares Issued on Exercise of Finders Warrants 13(b)(v) 712,000 368,127 - - (98,343) - - - 269,784 Shares Issued on Exercise of Stock Options 13(b)(vi) 1,760,000 1,463,811 - (443,061) - - - - 1,020,750 Fair Value of Stock Options Vested 13(f) - - - 1,042,560 - - - - 1,042,560 Fair Value of Stock Options Cancelled - - - (454,145) - - - 454,145 - Equity Component of Convertible Bonds Issued 12 - - - - - - 213,111-213,111 Net Comprehensive Loss - - - - - 200,538 - (9,602,035) (9,401,497) Balance, March 31, 2017 78,490,136 26,475,210-1,215,195 91,453 124,082 213,111 (17,452,418) 10,666,633 Shares Issued for Bonds Bonus 13(b)(vii) 46,800 39,780 - - - - - - 39,780 Shares Issued on Exercise of Warrants 13(b)(viii) 4,617,500 1,847,000 - - - - - - 1,847,000 Shares Issued on Exercise of Finders Warrants 13(b)(viii) 561,000 257,545 - - (33,145) - - - 224,400 Shares Issued on Exercise of Stock Options 13(b)(xi) 690,000 737,605 - (367,605) - - - - 370,000 Fair Value of Stock Options Vested 13(f) - - - 1,022,711 - - - - 1,022,711 Fair Value of Stock Options Cancelled - - - - (1,313) - - 1,313 - Warrant Subscription Advance - - 35,000 - - - - - 35,000 Net Comprehensive Loss - - - - - (165,994) (2,698,094) (2,864,088) Balance, June 30, 2017 84,405,436 29,357,140 35,000 1,870,301 56,995 (41,912) 213,111 (20,149,199) 11,341,436 The accompanying notes are an integral part of the consolidated financial statements. 3

Condensed Consolidated Interim Statements of Comprehensive Loss For the Three Months Ended June 30, 2017 and 2016 REVENUES 2017 2016 Note $ $ Rental 84,729 37,369 Consulting 30,260 28,994 Interest 3,183 - EXPENSES 118,172 66,363 Bank Charges and Interest 2,680 804 Consulting Fees 14(b),(c) 159,807 148,774 Commissions 475,479 - Directors Fees 14(b) 1,500 4,500 Insurance 21,101 - Management Fees 14(b) 30,000 30,000 Materials and Repairs 23,789 80,355 Office 25,211 654 Professional Fees 114,542 129,336 Rent and Utilities 38,578 45,822 Shareholder and Investor Relations 568,576 12,187 Transfer Agent and Filing Fees 2,047 10,071 Travel 30,943 26 1,494,253 462,529 LOSS BEFORE OTHER ITEMS (1,376,081) (396,166) Stock Based Compensation 13(f) (1,022,711) - Amortization of Intangible Assets (30,067) - Depreciation of Property and Equipment (49,453) (1,991) Finance Cost - (6,864) Interest on Convertible Bonds Payable 11 (33,120) - Accretion on Bonds (21,096) - Share of Loss in Equity Investment 12 (165,566) - NET LOSS FOR THE PERIOD (2,698,094) (405,021) Other Comprehensive Income for the Year Foreign Currency Translation Gain (165,994) (94,373) NET COMPREHENSIVE LOSS FOR THE PERIOD (2,864,088) (499,394) Basic and Diluted Loss per Share (0.04) (0.01) Weighted Average Number of Common Shares Outstanding 81,447,786 41,054,958 The accompanying notes are an integral part of the consolidated financial statements. 4

Condensed Consolidated Interim Statements of Cash Flows For the Three Months Ended June 30, 2017 and 2016 CASH PROVIDED BY (USED FOR): 2017 2016 $ $ OPERATING ACTIVITIES Net Loss for the Period (2,698,094) (405,021) Non-Cash Items Amortization of Intangible Assets 30,067 - Depreciation of Property and Equipment 49,453 1,991 Stock Based Compensation 1,022,711 - Accretion on Debentures 21,096 - Share of Loss in Equity Investment 165,566 - Shares Issued Services - 240,000 (1,409,201) (163,030) Change in Non-Cash Working Capital Accounts 17(a) (758,263) (442,646) FINANCING ACTIVITIES (2,167,464) (585,676) Shares Issued for Cash, Net of Issuance Costs - 1,091,500 Share & Warrant Subscriptions Advance 35,000 (443,000) Proceeds from Exercise of Warrants 1,847,000 - Proceeds from Exercise of Finders Warrants 224,400 - Proceeds from Exercise of Stock Options 370,000 - Loan Advanced to Arm s Length Party 5,439 - Net (Advance to) Repayment from Related Party 33,659 (254,886) Advances (Repayment) of Loan Payable - (3,946) INVESTING ACTIVITIES 2,515,498 389,668 Acquisition of Property and Equipment (611,529) (48,603) Acquisition of Land (1,537,458) - Acquisition of Intangible Assets (290,424) - (2,439,411) (48,603) INCREASE (DECREASE) IN CASH (2,091,377) (244,611) Effect of Foreign Exchange Rate Changes on Cash (98,028) (33,957) CASH, BEGINNING OF THE PERIOD 4,316,697 329,547 CASH, END OF THE PERIOD 2,127,292 50,979 Supplemental Cash Flow Information (Note 17) The accompanying notes are an integral part of the consolidated financial statements. 5

NOTE 1 NATURE OF OPERATIONS AND ABILITY TO CONTINUE AS A GOING CONCERN Marapharm Ventures Inc. (the Company ) is governed by the Business Corporations Act (British Columbia). The head office is located at Suite 102 1561 Sutherland Avenue, Kelowna, BC, Canada V1Y 5Y7. The Company's common shares are traded on the Canadian Stock Exchange ( CSE ) under the symbol "MDM". The Company was established to enter into the emerging market of regulated medical marijuana and has applied to Health Canada to become a licensed producer under the Access to Cannabis for Medical Purposes Regulations, which is still pending. The Company also has operations in the United States, in the State of Washington, Nevada, and California. The Company has marijuana cultivation and production licenses in Nevada. These consolidated financial statements have been prepared on the going concern basis, which assumes that the Company will be able to realize its assets and discharge its liabilities in the normal course of business. The Company s ability to continue as a going concern is dependent upon its ability to maintain its marijuana cultivation and production licenses in good standing, generate profitable operations, obtain the necessary debt or equity financing, and identify future investment opportunities. From inception to June 30, 2017, the Company has incurred losses from operations and has net accumulated losses of $20,149,199. As at June 30, 2017, the Company has working capital of $4,547,977 which is not sufficient to meet its operating and administrative costs and acquisition and other commitments. Although the Company has raised funds in the past and subsequent to June 30, 2017 (Note 20), there can be no assurance the Company will be able to secure sufficient debt or equity financing for its working capital and investment activities, in which case the Company may be unable to meet its obligations as they come due in the normal course of business. It is not possible to predict whether financing efforts will be successful or if the Company will attain profitable level of operations. These factors indicate the existence of a material uncertainty that may cast substantial doubt regarding the Company s ability to continue as a going concern. These consolidated financial statements do not include any adjustments to the recoverability or classifications of assets and liabilities that might be necessary should the Company be unable to continue operations. NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES a) Statement of Compliance These amended and restated condensed consolidated interim financial statements, including comparatives, have been prepared in accordance with International Accounting Standards ( IAS ) 34, Interim Financial Reporting using accounting policies consistent with IFRS issued by the International Accounting Standards Board ( IASB ) and interpretations of the IFRS Interpretations Committee ( IFRIC ). These condensed consolidated interim financial statements have been prepared on the basis of accounting policies and methods of computation consistent with those applied in and should be read in conjunction with the Company s March 31, 2017 consolidated financial statements. These amended and restated consolidated financial statements were approved and authorized for issue by the Board of Directors on August 28, 2017. b) Basis of Consolidation These amended and restated consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (collectively, the Company ). Intercompany balances and transactions are eliminated in preparing these consolidated financial statements. The following companies have been consolidated within these consolidated financial statements: 6

NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued) Entity Country of Incorporation Holding Functional Currency Marapharm Ventures Inc. Canada Parent Canadian Dollar Marapharm Inc. Canada 100% Canadian Dollar Marapharm Las Vegas LLC United States 100% U.S. Dollar Marapharm Washington LLC United States 100% U.S. Dollar EcoNevada LLC United States 100% U.S. Dollar c) Basis of Preparation These amended and restated condensed consolidated interim financial statements have been prepared on a historical cost basis. Cost is the fair value of the consideration given in exchange for net assets. d) Business Combination Acquisitions of businesses are accounted for using the acquisition method. The cost of the business combination is measured as the sum of the acquisition-date fair values of the assets transferred by the Company, liabilities incurred or assumed, and equity instruments issued by the Company in exchange for control of the acquiree. Acquisition-related costs are expensed as incurred. The Company recognizes identifiable assets acquired and liabilities assumed in a business combination regardless of whether they have been previously recognized in the acquiree's financial statements prior to the acquisition. Assets acquired and liabilities assumed are measured at their acquisition-date fair values. Goodwill is stated after separate recognition of identifiable intangible assets. It is calculated as the excess of the sum of: a) fair value of consideration transferred, b) the recognized amount of any non-controlling interest in the acquiree, and c) acquisition-date fair value of any existing equity interest in the acquiree, over the acquisition-date fair values of identifiable net assets. If the fair values of identifiable net assets exceed the sum calculated above, the excess amount is recognized in profit or loss as a bargain purchase gain. e) Foreign Currency These consolidated financial statements are presented in Canadian dollars, which is also the functional currency of the parent company. Each subsidiary determines its own functional currency (Note 2(b)) and items included in the financial statements of each subsidiary are measured using that functional currency. i) Transactions and Balances in Foreign Currencies Foreign currency transactions are translated into the functional currency of the respective entity, using the exchange rates prevailing at the dates of the transactions. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-measurement of monetary items at year-end exchange rates are recognized in profit or loss. Non-monetary items measured at historical cost are translated using the exchange rates at the date of the transaction and are not retranslated. Non-monetary items measured at fair value are translated using the exchange rates at the date when fair value was determined. 7

NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued) a) Impairment of Property and Equipment and Intangible Assets (Continued) ii) Foreign Operations On consolidation, the assets and liabilities of foreign operations are translated into Canadian dollars at the exchange rate prevailing at the reporting date and their income statements are translated at exchange rates prevailing at the dates of the transactions. The exchange differences arising on the translation are recognized in other comprehensive income and accumulated in the foreign currency translation reserve in equity. On disposal of a foreign operation, the component of other comprehensive income relating to that particular foreign operation is recognized in earnings and recognized as part of the gain or loss on disposal. b) Revenue Recognition Revenue is measured at the fair value of the consideration received or receivable, and is recorded to the extent that collection is reasonably assured. c) Property and Equipment Property and equipment are stated at cost less accumulated depreciation and accumulated impairment losses. Depreciation is provided on a straight-line basis over the following terms: Furniture and Equipment Leasehold Improvements 3 to 5 years 5 years Depreciation on buildings under construction will commence when they are available for use. The estimated useful lives, residual values and depreciation method are reviewed at the end of each reporting period, with the effect of any changes in estimate accounted for on a prospective basis. Gains and losses on disposal of property and equipment are determined by comparing the proceeds from disposal with the carrying amount and recognized in profit or loss. d) Intangible Assets Finite life intangible assets are recorded at cost less accumulated amortization and accumulated impairment losses. Amortization is provided on a straight-line basis over five years, the term of an underlying lease agreement, for a right to sublease the Company s leased property in the State of Washington to a marijuana cultivation and processing licensed company. The estimated useful life and amortization method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives are comprised of marijuana cultivation and production licenses issued by the State of Nevada, which are carried at cost less accumulated impairment losses. Intangible assets acquired are measured on initial recognition at cost, while the cost of intangible assets acquired in a business combination is initially recorded at their fair values as at the date of acquisition. An intangible asset is derecognized on disposal or when no future economic benefits are expected from use or disposal. Any gain or loss arising from de-recognition of an intangible asset is measured as the difference between the net disposal proceeds and the carrying amount of the asset and is recognized in profit or loss. 8

NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued) e) Impairment of Property and Equipment and Intangible Assets At the end of each reporting period, the Company reviews the carrying amounts of its property and equipment and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. Individual assets are grouped together as a cash generating unit for impairment assessment purposes at the lowest level at which there are identifiable cash flows that are independent from other group assets If any such indication of impairment exists, the Company makes an estimate of its recoverable amount. The recoverable amount is the higher of fair value less costs to sell and value in use. Where the carrying amount of a cash generating unit exceeds its recoverable amount, the cash generating unit is considered impaired and is written down to its recoverable amount. In assessing the value in use, the estimated future cash flows are adjusted for the risks specific to the cash generating unit and are discounted to their present value with a discount rate that reflects the current market indicators. Where an impairment loss subsequently reverses, the carrying amount of the cash generating unit is increased to the revised estimate of its recoverable amount, to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognized for the cash generating unit in prior years. A reversal of an impairment loss is recognized as income immediately. f) Convertible Bonds Payable Convertible bonds payable are compound financial instruments that are recorded in part as a liability and in part as shareholders equity. The Company uses the residual valuation method to determine the debt and equity components of the convertible debentures. Under the residual valuation method, the liability component is determined by estimating the present value of the future cash payments discounted at a rate of interest which the Company would be charged by the market for similar debt without the conversion option. The difference between the net proceeds of the debenture and the liability component is recorded as a separate component of shareholders equity. Convertible bonds payable is accreted to its face value at maturity over the term of the debt through a charge to operations. The value of the equity component is not re-measured subsequent to its initial measurement date, and remains in equity until the conversion option is exercised, in which case, the balance recognized in equity will be transferred to share capital. On the early redemption of convertible bonds, the Company allocates the consideration paid on extinguishment to the liability based on its fair value at the date of the transaction and the residual is allocated to the conversion option. Any resulting gain or loss relating to the liability component is charged to profit or loss, and the difference between the carrying amount and the amount considered to be settled relating to the equity component is treated as a capital transaction and charged to share capital. g) Provisions Provisions are recognized when the Company has a present legal or constructive obligation as a result of a past event, is probable that an outflow of resources embodying economic benefits will be required to settle the obligation, and a reliable estimate can be made of the amount of the obligation. The amount recognized as a provision is the best estimate of the consideration required to settle the present obligation at the end of the reporting period, taking into account the risks and uncertainties surrounding the obligation. As at June 30, 2017 and March 31, 2017, the Company has no material provisions. 9

NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued) h) Share Capital and Share Subscriptions Cash consideration received from the issuance of units, consisting of common shares and share purchase warrants, are first allocated to common shares based on the quoted market value of the common shares at the time the units are priced, and the balance, if any, is allocated to the attached warrants under the residual method. Share issue costs are netted against share capital. Share subscriptions represent proceeds received for shares that have not yet been issued as at the reporting date. Shares issued for non-monetary consideration are recorded at fair value of the goods or services received. When such fair value cannot be estimated reliably, fair value is measured based on the quoted market value of the Company s shares on the date of share issuance. i) Loss Per Share Loss per share is calculated using the weighted average number of common shares issued and outstanding during the reporting period. Diluted loss per share is the same as basic loss per share, as the issuance of shares on the exercise of stock options and share purchase warrants is anti-dilutive. j) Reserves Stock options reserve and share purchase warrants reserve are used to recognize the fair value of stock options and warrants prior to their exercise, expiry, or cancellation. Fair value of stock options and finder s warrants is determined on the date of grant using the Black-Scholes Model (Note 2(p)). k) Share-Based Payments The fair value method of accounting is used for share-based payment transactions. Under this method, the cost of stock options and finders warrants is recorded based on the estimated fair value using the Black-Scholes option-pricing model at the grant date and charged to profit over the vesting period. The amount recognized as an expense is adjusted to reflect the number of equity instruments expected to vest. Upon the exercise of stock options and finders warrants, consideration received on the exercise of these equity instruments is recorded as share capital and the related share-based payment reserve is transferred to share capital. Upon the expiry or cancellation of stock options and finders warrants, their fair value previously recorded in reserve is transferred to deficit l) Income Taxes Tax expense recognized in profit or loss comprises the sum of deferred tax and current tax not recognized in other comprehensive income or directly in equity. i) Current Income Tax Current income tax assets and/or liabilities comprise those claims from, or obligations to, fiscal authorities relating to the current or prior reporting periods that are unpaid at the reporting date. Current tax is payable on taxable profit, which differs from profit or loss in the consolidated financial statements. Calculation of current tax is based on tax rates and tax laws that have been enacted or substantively enacted by the end of the reporting period. 10

NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued) ii) Deferred Income Tax Deferred income taxes are calculated using the liability method on temporary differences between the carrying amounts of assets and liabilities and their tax bases. Deferred tax assets and liabilities are calculated, without discounting, at tax rates that are expected to apply to their respective period of realization, provided they are enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are always provided for in full. Deferred tax assets are recognized to the extent that it is probable that they will be able to be utilized against future taxable income. Deferred tax assets and liabilities are offset only when the Company has a right and intention to offset current tax assets and liabilities from the same taxation authority. Changes in deferred tax assets or liabilities are recognized as a component of tax income or expense in profit or loss, except where they relate to items that are recognized in other comprehensive income or directly in equity, in which case the related deferred tax is also recognized in other comprehensive income or equity, respectively. m) Financial Instruments Financial assets and financial liabilities are recognized when the Company becomes a party to the contractual provisions of the financial instrument. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities classified at fair value through profit or loss) are added to, or deducted from, the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities classified at fair value through profit or loss are recognized immediately in profit or loss. Financial assets and financial liabilities are measured subsequently as described on the following pages. The Company does not have any derivative financial instruments. i) Financial Assets For the purpose of subsequent measurement, financial assets other than those designated and effective as hedging instruments are classified into the following categories upon initial recognition: Financial assets at fair value through profit or loss; Loans and receivables; Held-to-maturity investments; and Available-for-sale financial assets. The category determines subsequent measurement and whether any resulting income and expense is recognized in profit or loss or in other comprehensive income. All financial assets except for those at fair value through profit or loss are subject to review for impairment at least at each reporting date. Financial assets are impaired when there is any objective evidence that a financial asset or a group of financial assets is impaired. Different criteria to determine impairment are applied for each category of financial assets, which are described on the next page. 11

NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued) r) Financial Instruments (Continued) i) Financial Assets (Continued) Financial assets at fair value through profit or loss Financial assets at fair value through profit or loss include financial assets that are either classified as held for trading or that meet certain conditions and are designated at fair value through profit or loss upon initial recognition. All derivative financial instruments fall into this category, except for those designated and effective as hedging instruments. Assets in this category are measured at fair value with gains or losses recognized in profit or loss. The Company s cash falls into this category of financial assets. Loans and receivables Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. After initial recognition, these are measured at amortized cost using the effective interest method, less any provision for impairment. Discounting is omitted where the effect of discounting is immaterial. The Company s trade and other receivables, loan receivable, and amount due from related party fall into this category of financial instruments. Individually significant receivables are considered for impairment when they are past due or when other objective evidence is received that a specific counterparty will default. Receivables that are not considered to be individually impaired are reviewed for impairment in groups, which are determined by reference to the industry and region of a counterparty and other shared credit risk characteristics. The impairment loss estimate is based on recent historical counterparty default rates for each identified group. The impairment losses are recognized in profit or loss. Held-to-maturity investments Held-to-maturity investments are non-derivative financial assets with fixed or determinable payments and fixed maturity, other than loans and receivables. Investments are classified as held-to-maturity if the Company has the intention and ability to hold them until maturity. The Company does not hold financial assets in this category. Available-for-sale financial assets Available-for-sale financial assets are non-derivative financial assets that are either designated to this category or do not qualify for inclusion in other categories of financial assets. The Company does not hold financial assets in this category. Available-for-sale financial assets are measured initially at fair value. The Company s investments in equity instruments are subsequently measured at cost as they do not have a quoted market price in an active market and their fair value cannot be reliably measured. For financial assets measured at amortized cost, if in a subsequent period the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognized, then the previously recognized impairment loss is reversed through profit or loss to the extent that the carrying amount of the investment at the date the impairment is reversed does not exceed what the amortized cost would have been had the impairment not been recognized. In respect of available-for-sale financial assets, impairment losses previously recognized in profit or loss are not reversed through profit or loss. Any increase in fair value subsequent to an impairment loss is recognized in other comprehensive income and accumulated in the investment revaluation reserve. 12

NOTE 2 BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Continued) r) Financial Instruments (Continued) i) Financial Assets (Continued) Financial assets are derecognized when the contractual rights to the cash flows from the financial asset expire, or when the financial asset and all substantial risks and rewards are transferred. For the purpose of subsequent measurement, financial liabilities are classified as either financial liabilities at fair value through profit or loss, or other financial liabilities upon initial recognition. Financial liabilities at fair value through profit or loss Financial liabilities at fair value through profit or loss include financial liabilities that are either classified as held for trading or that meet certain conditions and are designated at fair value through profit or loss upon initial recognition. Liabilities in this category are measured at fair value with gains or losses recognized in profit or loss. The Company currently does not hold financial liabilities in this category. Other financial liabilities Other financial liabilities are subsequently measured at amortized cost using the effective interest method. Gains and losses are recognized in the income statement when the liabilities are derecognized as well as through the effective interest rate method amortization process. The Company s trade and other payables, amounts due to related parties, loan payable, and convertible bonds payable fall into this category of financial instruments. A financial liability is derecognized when it is extinguished, discharged, cancelled or expired. s) Comparative Figures Certain comparative figures have been reclassified to conform to the financial statement presentation adopted for the current period. These reclassifications have no effect on the consolidated net loss for the three months ended June 30, 2016 except for restatements beginning in June 2016 to recognize rental and consulting income from its Washington State operations in the amount of $66,363. This amount was offset by an increase in the Foreign Currency Translation Loss of $94,373 for a net increase in Net Comprehensive Loss for the Period of $24,877. NOTE 3 SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS In the application of the Company s accounting policies which are described in Note 2, management is required to make judgments, estimates, and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods. Significant estimates and assumptions that have the most significant effect on the amounts recognized in the consolidated financial statements are described as follows. a) Impairment of Property and Equipment and Intangible Assets 13

NOTE 3 SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUMPTIONS (Continued) An impairment loss is recognized for the amount by which the asset's or cash-generating unit's carrying amount exceeds its recoverable amount. To determine the recoverable amount, management estimates expected future cash flows from each asset or cash-generating unit and determines a suitable interest rate in order to calculate the present value of those cash flows. In the process of measuring expected future cash flows, management makes assumptions about future operating results. In addition, when determining the applicable discount rate, estimation is involved in determining the appropriate adjustments to market risk and asset-specific risk factors. These assumptions relate to future events and circumstances. Actual results may vary and may cause significant adjustments to the Company s assets within the next financial year. b) Useful Lives of Property and Equipment and Intangible Assets Management reviews the useful lives of property and equipment and intangible assets at each reporting date, based on the expected utility of these assets to the Company. The useful lives of these assets may be shortened due to factors such as regulatory changes in the marijuana industry that are beyond the Company s control. c) Business Combination On initial recognition, the assets and liabilities of the acquired business and the consideration paid for them are included in the consolidated financial statements at their fair values. In measuring fair value, management uses estimates of future cash flows and discount rates. Any subsequent change in these estimates would affect the amount of goodwill if the change qualifies as a measurement period adjustment. Any other change would be recognized in the income statement in the subsequent period. d) Stock Based Compensation The fair value of stock based compensation is subject to the limitations of the Black-Scholes option pricing model that incorporates market data and involves uncertainty in estimates used by management in the assumptions. Because the Black-Scholes option pricing model requires the input of highly subjective assumptions, including the volatility of share prices, changes in subjective input assumptions can materially affect the fair value estimate. e) Deferred Tax Assets Deferred tax assets, including those arising from unutilized tax losses, require management to assess the likelihood that the Company will generate sufficient taxable earnings in future periods in order to utilize recognized deferred tax assets. Assumptions about the generation of future taxable profits depend on management s estimates of future cash flows. In addition, future changes in tax laws could limit the ability of the Company to obtain tax deductions in future periods. To the extent that future cash flows and taxable income differ significantly from estimates, the ability of the Company to realize the net deferred tax assets recorded at the reporting date could be impacted. The Company has recorded a full valuation allowance against its deferred tax assets due to the uncertainty in the realization of these assets. NOTE 4 ACCOUNTING STANDARDS ISSUED BUT NOT YET EFFECTIVE A number of new accounting standards, amendments to standards, and interpretations have been issued but not yet effective up to the date of issuance of the Company s consolidated financial statements. The Company intends to adopt the following standards when they become effective. 14

NOTE 4 ACCOUNTING STANDARDS ISSUED BUT NOT YET EFFECTIVE (Continued) a) IFRS 9 Financial Instruments IFRS 9 will replace IAS 39 Financial Instruments: Recognition and Measurement and applies to the classification and measurement of financial assets. The mandatory effective date is January 1, 2018 with early adoption permitted. The Company currently does not intend to early adopt IFRS 9. The Company has not yet determined the impact of this standard on its consolidated financial statements. b) IFRS 15 Revenue from Contracts with Customers IFRS 15 clarifies the principles for recognizing revenue from contracts with customers. IFRS 15 will also result in enhanced disclosures about revenue, provide guidance for transactions that were not previously addressed comprehensively, and improve guidance for multiple-element arrangements. The standard is effective for annual periods beginning on or after January 1, 2018 and is to be applied retrospectively. The Company has not yet determined the impact of this standard on its consolidated financial statements. c) IFRS 16 Leases IFRS 16 provides a single lessee accounting model, requiring the recognition of assets and liabilities for all leases, unless the lease term is 12 months or less or the underlying asset has a low value. Lessor accounting remains largely unchanged from IAS 17 Leases, and the distinction between operating and finance leases is retained. The standard is effective for annual period beginning on or after January 1, 2019. The Company has not yet determined the impact of this standard on its consolidated financial statements. NOTE 5 TRADE AND OTHER RECEIVABLES June 30 March 31 2017 2017 $ $ Trade Receivable 487,286 385,671 GST Recoverable 26,990 24,276 Share Subscription Receivable (Note 13(b)(v)) - 308,000 514,276 717,947 NOTE 6 PREPAID EXPENSES AND DEPOSITS Retainer on Delivery Service Agreement (Note 14(c)(v)) 389,310 398,970 Deposit and Instalment on Acquisition of Washington Property (Note 20(e) 1,167,930 797,940 Deposit on Option to Acquire Marijuana Cultivation License (Note 15(d) 6,489 6,650 Deposit on Acquisition of California Properties (Note 20(a)(b) 130,422 179,995 Security Deposits 36,955 32,184 Surety Bond on Las Vegas Construction Project 502,073 15,666 Other Prepaid Expenses 173,405 141,567 2,406,584 1,572,972 15

NOTE 7 LOAN RECEIVABLE On August 29, 2016, the Company advanced US$225,000 to the subtenant of its leased property in Washington. The unsecured loan is subject to an interest rate of 5% commencing April 15, 2017 and repayable over a five-year period in blended monthly payments of US$4,241. The Company has agreed to waive the monthly repayment requirement until completion of the renovations at the leased property, anticipated to be in the fourth quarter of fiscal 2018, when retroactive loan repayments will be made. The Company has accrued $1,804 (US$1,391) in interest revenue in the three months ended June 30, 2017. As at June 30, 2017, the outstanding balance of the loan was $293,788 (US$226,391). NOTE 8 PROPERTY AND EQUIPMENT COST Land Furniture and Equipment Leasehold Improvements Buildings Under Construction Total $ $ $ $ $ Balance, March 31, 2016 1,319,708 5,797 36,228-1,361,733 Additions 150,891 402,037 463,080 927,608 1,943,616 Foreign Currency Translation Adjustment 77,739 5,177 6,005 12,030 100,951 Balance, March 31, 2017 1,548,338 413,011 505,313 939,638 3,406,300 Additions 1,537,458 36,958 13,514 561,057 2,148,987 Foreign Currency Translation Adjustment (19,504) (10,490) (11,832) (42,443) (84,268) Balance, June 30, 2017 3,066,292 439,479 506,995 1,458,252 5,471,019 ACCUMULATED DEPRECIATION Balance, March 31, 2016 725,345 1,127 2,216-728,688 Depreciation Charge - 60,775 67,282-128,057 Foreign Currency Translation Adjustment 17,427 762 (215)- - 17,974 Balance March 31, 2017 742,772 62,664 69,283-874,719 Depreciation Charge - 23,248 26,205-49,454 Foreign Currency Translation Adjustment 1,626 (6,126) - (4,500) Balance June 30, 2017 742,772 87,538 89,362-919,673 NET BOOK VALUE Balance, March 31, 2017 805,566 350,347 436,030 939,638 2,531,581 Balance, June 30, 2017 2,323,520 351,941 417,633 1,458,252 4,551,346 16

NOTE 9 INTANGIBLE ASSETS COST Hemp Products Marijuana Sublease Formula Licenses Right Total $ $ $ $ Balance, March 31, 2016 50,000 - - 50,000 Additions - 1,099,160 587,019 1,686,179 Foreign Currency Translation Adjustment - 14,254 7,613 21,867 Balance, March 31, 2017 50,000 1,113,414 594,632 1,758,046 Additions - 290,424-290,424 Foreign Currency Translation Adjustment - (37,149) (14,398) (51,547) Balance, June 30, 2017 50,000 1,366,689 580,234 1,996,923 ACCUMULATED AMORTIZATION Balance, March 31, 2016 49,999 - - 49,999 Amortization Charge - - 88,786 88,786 Foreign Currency Translation Adjustment - - 408 408 Balance, March 31, 2017 49,999-89,194 139,193 Amortization Charge - - 30,067 30,067 Foreign Currency Translation Adjustment - - (3,215) (3,215) Balance, June 30, 2017 49,999-116,046 166,045 NET BOOK VALUE Balance, March 31, 2017 1 1,113,414 505,438 1,618,853 Balance, June 30, 2017 1 1,366,689 464,188 1,830,878 a) Hemp Products Formula On November 24, 2014, the Company entered into an agreement to acquire a hemp-blended formula to produce shampoo, conditioner, fragrances, and other hemp products. The purchase price was $50,000. On March 31, 2016, the Company recorded an impairment loss of $49,999 due to the uncertainty of future cash flows relating to the sale of these products. b) Marijuana Licenses During the year ended March 31, 2017, the Company completed the acquisition of Econevada LLC ( Econevada ), a company that owned two provisional medical cultivation and production licenses from the State of Nevada. Both licenses received final approval from the State of Nevada and were transferred to Marapharm Las Vegas LLC. The Company purchased a 75.5% interest in Econevada from a related party and paid US$375,000 in cash and issued 1,072,813 common shares with a fair value of US$336,125 (Note 13(b)(ii)). The Company acquired the remaining 24.5% interest in Econevada from arm s length parties and issued 100,001 common shares with a fair value of US$115,491. Total consideration for this acquisition was US$826,616. 17

NOTE 9 INTANGIBLE ASSETS (Continued) c) Sublease Right In May 2016, the Company acquired certain assets from a marijuana cultivation and processing licensed company ( Subtenant ) in the State of Washington. Cash consideration of US$975,000 was paid and allocated to equipment for US$295,564, leasehold improvements for US$232,311, and a sublease right for US$447,125. The sublease right allows the Company to sublease its leased industrial property in Washington to the Subtenant for a term of 20 years with an option to renew for another five years. The Company agreed to complete extensive improvements to the property in order to provide the Subtenant with a fully equipped operational facility. Monthly sublease rent is set at $21,000 and will retroactively increase to $200,000 upon completion of the current renovations at the property pursuant to a sublease agreement dated August 10, 2016 and amended on August 18, 2016. The underlying lease agreement between the Company and the land owner has a term of five years effective July 1, 2016, with an option to renew for another five years (Note 15(a)). In February 2017, the Company entered into property purchase agreement with the land owner to acquire the property for US$4,200,000 (Note 20(e)). NOTE 10 TRADE AND OTHER PAYABLES June 30 March 31 2017 2017 $ $ Trade Payables and Accrued Liabilities 493,095 575,677 Holdback Payable 32,614 24,675 Directors Fees Payable (Note 14(a)) 10,500 9,000 Bond Bonus Payable (Note 12) - 46,679 536,209 656,031 NOTE 11 CONVERTIBLE BONDS PAYABLE Liability Component Equity Component Net Carrying Value $ $ $ Balance, March 31, 2017 1,287,676 213,111 1,500,787 Balance June, 30 2017 1,208,857 213,111 1,421,968 On March 31, 2017, the Company closed a non-brokered private placement of 117 convertible bonds at an issue price of US$10,000 per bond for total gross proceeds of $1,555,943 (US$1,170,000). The bonds, in part or in full, are convertible into common shares of the Company at the conversion price of $1 per share in the first year, $2 per share in the second year, and $3 per share in the third year. The bonds mature on November 30, 2019 and bear compound interest at 8.5% per annum with interest payable monthly. The bonds are open for prepayment without penalty and are secured by the assets of Marapharm Las Vegas LLC which included land, buildings under construction, and marijuana licenses in the State of Nevada. The Company agreed to issue a 3% bonus interest (US$300) for each bond issued, payable in common shares. On May 1, 2017 the Company issued 46,800 common shares (Note 13 (b)(vii)). 18

NOTE 11 CONVERTIBLE BONDS PAYABLE (Continued) The convertible debentures are recorded in part as a liability and in part as shareholders equity. The Company uses the residual valuation method to determine the debt and equity components of the convertible debentures. Under the residual valuation method, the liability component is determined by estimating the present value of the future cash payments discounted at a rate of interest which the Company would be charged by the market for similar debt without the conversion option. The difference between the net proceeds of the debenture and the liability component is recorded as a separate component of shareholders equity. NOTE 12 INVESTMENT IN ASSOCIATE On January 4, 2017 the Company subscribed for 5,000,000 units in a private placement offering of Veritas Pharma Inc. ( Veritas ) at a price of $0.22 per unit for total proceeds of $1,100,000. Each unit consists of one common share and one share purchase warrant. Each warrant is exercisable for one additional common share at $0.30 per share until July 9, 2018. Veritas is working to develop the most effective proprietary cannabis strains for specific disease conditions and to provide doctors and patients with conclusive science evidence to recommend and use medical marijuana. Concurrent to the unit subscription, the Company subscribed for 5,000,000 warrants of Veritas at a price of $0.05 per warrant for total proceeds of $250,000. Each warrant is exercisable for one additional common share at $0.40 per share until February 7, 2018. Following this investment, the Company appointed two common directors to Veritas and as at March 31, 2017, had a 11.52% ownership interest in Veritas. The Company accounts for its investment in Veritas using the equity method. The Company has recognized its proportionate share of Verita s net loss for the period ended March 31, 2017 in the amount of $111,868. For the period ended June 30, 2017, the Company recognized a loss of $165,566 on the consolidated statement of comprehensive loss. As at June 30, 2017, the carrying amount of the Company s investment in Veritas was $1,072,566. NOTE 13 SHARE CAPITAL a) Authorized Share Capital The Company is authorized to issue an unlimited number of common shares without par value. b) Issued and Outstanding Common Shares As at June 30, 2017, the Company had 84,405,436 common shares issued and outstanding as presented in the consolidated statements of changes in shareholders equity. Shares Issued For the Year Ended March 31, 2017 i) Shares Issued for Cash On April 14, 2016, the Company issued 2,640,000 units at $0.20 per unit for total gross proceeds of $528,000. Each unit consisted of one common share and one share purchase warrant exercisable at $0.40 until April 14, 2017. The Company issued 89,000 common shares with a fair value of $17,800 and 379,000 finders warrants with a fair value of $23,783 for finders fees. As at March 31, 2016, the Company received $443,000 in share subscriptions prior to the closing of the private placement. 19

NOTE 13 SHARE CAPITAL (Continued) On June 16, 2016, the Company issued 2,817,500 units at $0.20 per unit for total gross proceeds of $563,500. Each unit consisted of one common share and one share purchase warrant exercisable at $0.40 until June 16, 2017. The Company issued 47,500 common shares with a fair value of $9,500 and 226,000 finder s warrants with a fair value of $11,924 for finders fees. On September 6, 2016, the Company issued 10,866,250 units at $0.20 per unit for total proceeds of $2,173,250. Each unit consisted of one common share and one share purchase warrant exercisable at $0.40 until September 6, 2017. The Company issued 352,500 common shares with a fair value of $70,500 and 1,022,500 finder s warrants with a fair value of $130,135 for finders fees. ii) Shares Issued for Intangible Assets During the year ended March 31, 2017, the Company issued a total of 1,172,814 common shares with a fair value of $594,855 (US$451,616) for the acquisition of Econevada (Note 9(b)(ii)). iii) Shares Issued for Services During the year ended March 31, 2017, the Company issued 435,000 common shares with a fair value of $287,150 to arm s length parties for marketing and investor relations services, of which $215,519 was related to services provided and expensed in the year ended March 31, 2016. During the year ended March 31, 2017, the Company issued 3,536,298 common shares with a fair value of $4,123,312 to a related party for marketing and investor relations services. During the year ended March 31, 2017, the Company issued 127,249 common shares with a fair value of $108,016 to arm s length parties for consulting services. iv) Shares Issued for Debt During the year ended March 31, 2017, the Company issued 188,702 common shares with a fair value of $137,752 to settle an outstanding loan. Included in the amount was $102,808 in principal and $34,944 in interest. v) Shares Issued on Exercise of Warrants During the year ended March 31, 2017, Company issued a total of 15,712,750 common shares upon the exercise of warrants for total gross proceeds of $9,803,062, and 712,000 common shares upon the exercise of finders warrants for total gross proceeds of $293,738. As at March 31, 2017, a receivable of $308,000 was recorded for outstanding subscription proceeds for the exercise of warrants, which was subsequently received in April 2017. vi) Shares Issued on Exercise of Stock Options During the year ended March 31, 2017, Company issued a total of 1,760,000 common shares upon the exercise of options for total gross proceeds of $1,020,750. Shares Issued For the Three Months Ended June 30, 2017 vii) Shares Issued for Bond Bonus On May 01, 2017, the Company issued 46,800 common shares for the 3% bonus interest (US$300) for each bond issued, payable in common shares at a deemed price of $0.85 per share. 20